On-treatment platelet reactivity in the era of new ADP receptor blockers: data from a real-world clinical practice

[1] Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505 - 151610.1016/j.jacc.2006.11.04417418288Search in Google Scholar

[2] Fedor M, Samoš M, Šimonová R., et al. Monitoring the Efficacy of ADP Inhibitor Treatment in Patients With Acute STEMI Post-PCI by VASP-P Flow Cytometry Assay. Clin Appl Thromb Hemost. 2015; 21: 334 – 338.10.1177/107602961454003624989714Search in Google Scholar

[3] Lhermusier T, Lipinski MJ, Tantry US, Escarcega RO, Baker N, Bliden KP et al. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. Am J Cardiol 2015; 115: 716 - 723.10.1016/j.amjcard.2014.12.02925728845Search in Google Scholar

[4] Paarup Dridi N, Johansson PI, Lønborg JT, et al. Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. Platelets. 2014; 28: 1 - 9.Search in Google Scholar

[5] Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–201510.1056/NEJMoa070648217982182Search in Google Scholar

[6] Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045 - 1057.10.1056/NEJMoa090432719717846Search in Google Scholar

[7] Cayla G, Cuisset T, Silvain J, et al. Prasugrel monitoring and bleeding in real world patients. Am J Cardiol 2013; 111: 38 - 44.10.1016/j.amjcard.2012.08.04323040597Search in Google Scholar

[8] Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011; 58: 467 - 473.10.1016/j.jacc.2011.04.01721777742Search in Google Scholar

[9] Roberts DI, Nawarskas JJ. Treatment options for patients with poor clopidogrel response. Cardiol Rev 2013; 21: 309 - 317.10.1097/CRD.0b013e3182a72fab24096929Search in Google Scholar

[10] Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011; 305: 1097 - 1105.10.1001/jama.2011.29021406646Search in Google Scholar

[11] Christ G, Siller-Matula JM, Francesconi M, et al. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open 2014; 4:e005781.10.1136/bmjopen-2014-005781421686725361837Search in Google Scholar